Should I Stop Opzelura If I'm Not Seeing Progress?
“Is this actually working?” is one of the most common questions about Opzelura, and the honest answer requires a timeline that’s longer than most people expect going in — which is exactly why stopping too early is one of the more common, and most avoidable, reasons people give up on a treatment that might have worked.
The timeline that actually matters
The clinical trials that led to Opzelura’s FDA approval measured meaningful results at 24 weeks — about six months — with continued improvement observed through 52 weeks (a full year) of use. This is the actual evidence-based timeline, not a marketing exaggeration: repigmentation is a genuinely slow biological process, and judging results before 3 to 4 months have passed is, in almost all cases, too early to draw a real conclusion.
If you’re at 6 or 8 weeks and frustrated by a lack of visible change, that frustration is understandable, but it’s not yet meaningful data about whether the treatment is working for you.
What “working” actually looks like early on
The first sign of response is usually not a patch becoming visibly smaller or more evenly pigmented — it’s small dots of pigment appearing around hair follicles within the patch, called perifollicular repigmentation. This dotted pattern is the expected first sign of response, and it can look unimpressive compared to what people picture (“the patch getting better”) even though it’s a genuinely positive sign that the treatment is doing its job.
Over additional months, these dots typically expand and can merge, gradually restoring more even pigmentation. If you’re checking for “is this working” by looking for whole-patch change rather than these early follicular dots, you may miss the actual signal that treatment is progressing.
Why response varies so much by location
It’s extremely common — expected, even — for Opzelura to work well on some patches and poorly on others in the same person. Facial and neck patches generally respond best in the clinical trial data. Hands, feet, and other acral sites respond much more slowly and often incompletely, for biological reasons related to hair follicle density in those areas, not because the treatment or your use of it is somehow wrong.
A common source of unnecessary discouragement is judging your overall treatment success by your least-responsive area (often the hands) rather than recognizing that different body locations are genuinely expected to respond differently.
A reasonable framework for when to actually reassess
Before 3 months: Too early to draw conclusions in almost all cases. Continue as prescribed unless you’re experiencing side effects that need addressing.
3 to 6 months: A reasonable first checkpoint. Look specifically for perifollicular dots or any early repigmentation, not necessarily dramatic change. Discuss what you’re seeing (or not seeing) with your dermatologist at this point.
6 to 12 months: This is where the clinical trial data suggests meaningful assessment becomes reliable. If you’re seeing genuinely zero change — no perifollicular dots, no change anywhere — by this point, that’s useful information worth a real conversation with your dermatologist about next steps.
Beyond 12 months with zero response anywhere: This is a reasonable point to discuss whether Opzelura is the right treatment for your specific case, whether combination therapy (adding NB-UVB) might help, or whether a different approach makes more sense — not a failure on your part, just useful clinical information.
What to discuss with your dermatologist rather than deciding alone
If you’re genuinely uncertain whether to continue, this is a conversation for your dermatologist rather than a decision to make solo based on a rough sense of “it’s not working.” Bring specific observations — which areas, what you’re seeing or not seeing, how consistently you’ve been applying it — rather than a general impression, since consistency of use is itself a variable worth checking honestly before concluding the treatment itself is the problem.
My take
The single most common mistake I see is judging Opzelura on a timeline that doesn’t match how it actually works. Six months is the real benchmark, not six weeks. If you’re genuinely at the year mark with zero change anywhere, that’s meaningful information and a fair reason to have the “what’s next” conversation — but getting there requires actually giving it the time the evidence says it needs first.
